Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903160 · ClinicalTrials.gov registry record · Phase 2
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02903160 is a Phase 2 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 40 participants.
The verdict
NCT02903160, a Phase 2 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and sequencing of therapies can help prevent or delay the development of therapeutic drug resistance, and can be safely tolerated.
Interventions
- DRUG Carboplatin
- DRUG Prednisone
- DRUG Abiraterone acetate
- DRUG Radium-223 dichloride
- DRUG cabazitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-01-13 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903160
The ClinicalTrials.gov registry entry for NCT02903160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02903160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02903160 about?
NCT02903160 is a clinical study titled "Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)". The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and s...
What is the current status of trial NCT02903160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-01-13. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT02903160?
The interventions under investigation include: Carboplatin (DRUG), Prednisone (DRUG), Abiraterone acetate (DRUG), Radium-223 dichloride (DRUG), cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT02903160?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.